Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised…

By D. Krag, Stewart J. Anderson, Thomas B. Julian, Ann M. Brown, S. Harlow, T. Ashikaga, Donald L. Weaver, B. Miller, L. Jalovec, T. Frazier and 8 more. The Lancet Oncology, 2007

996 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/f7e160c6ba05310f395fd0a5aac47f1661f63bd8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Boileau
2. G. Lyman
3. H. Burstein
4. S. Temin
5. B. Poirier
6. A. Giuliano
7. Stephen B Edge
8. M. Basik

Citations in the corpus

• Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. (2014, methodology): “Five trials reported on recurrence.(3,5,6,9,16) They found that the rates of in-breast local recurrence, axillary recurrence, and distant recurrence were similar with SNB alone and with SNB plus ALND.”
• Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. (2015, result): “It was hypothesized that the FNR would be 10%, similar to the rate reported in the NSABP B-32 trial.(12) The other main objective of this study was to evaluate the IR of SNB in this setting (estimated at 90%).”